Zacks.com on MSN19h
CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?
CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and ...
Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...
Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US
This achievement follows Bahrain’s landmark decision on 2 December 2023 to become the second country globally and the first ...
Zacks.com on MSN11d
CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...
CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...
Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...
Nasdaq6d
CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates
CRISPR Therapeutics CRSP reported fourth-quarter ... primarily comprising collaboration revenues received from Vertex Pharmaceuticals VRTX in connection with the approval of Casgevy for two ...